TGFBR3 downregulation is the most common modification of the TGF-β signaling pathway in prostate cancer and contributes to stimulation of cancer cells’ motility and invasiveness in vitro as well as enhanced tumorigenicity in vivo [241]. Here, TGFB1 is linked to prostate carcinoma.